These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 39002529)

  • 1. Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine.
    Drosos P; Johnsen E; Bartz-Johannessen CA; Larsen TK; Reitan SK; Rettenbacher M; Kroken RA
    Schizophr Res; 2024 Sep; 271():9-18. PubMed ID: 39002529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).
    Kjelby E; Gjestad R; Fathian F; Sinkeviciute I; Alisauskiene R; Anda L; Løberg EM; Reitan SK; Joa I; Larsen TK; Rettenbacher M; Berle JØ; Fasmer OB; Kroken RA; Johnsen E
    J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):246-258. PubMed ID: 37083542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study.
    Alisauskiene R; Johnsen E; Gjestad R; Kroken RA; Kjelby E; Sinkeviciute I; Fathian F; Joa I; Reitan SK; Rettenbacher M; Løberg EM
    Gen Hosp Psychiatry; 2023; 83():185-193. PubMed ID: 37269769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
    Mørkved N; Johnsen E; Kroken RA; Winje D; Larsen TK; Thimm JC; Rettenbacher MA; Johannesen CAB; Løberg EM
    Schizophr Res; 2022 Aug; 246():49-59. PubMed ID: 35709647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness.
    Drosos P; Johnsen E; Bartz-Johannessen CA; Larsen TK; Reitan SK; Rettenbacher M; Kroken RA
    World J Psychiatry; 2022 Mar; 12(3):521-532. PubMed ID: 35433321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.
    Kahn RS; Winter van Rossum I; Leucht S; McGuire P; Lewis SW; Leboyer M; Arango C; Dazzan P; Drake R; Heres S; Díaz-Caneja CM; Rujescu D; Weiser M; Galderisi S; Glenthøj B; Eijkemans MJC; Fleischhacker WW; Kapur S; Sommer IE;
    Lancet Psychiatry; 2018 Oct; 5(10):797-807. PubMed ID: 30115598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; Bhoopathi PS; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006627. PubMed ID: 19821380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amisulpride for schizophrenia.
    Mota NE; Lima MS; Soares BG
    Cochrane Database Syst Rev; 2002; 2002(2):CD001357. PubMed ID: 12076408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.
    Stabell LA; Johnsen E; Kroken RA; Løberg EM; Blindheim A; Joa I; Reitan SK; Rettenbacher M; Munk-Jørgensen P; Gjestad R
    BMC Psychiatry; 2023 Jun; 23(1):482. PubMed ID: 37386462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.
    Sinkeviciute I; Hugdahl K; Bartz-Johannessen C; Kroken RA; Løberg EM; Kjelby E; Rettenbacher MA; Joa I; Reitan SK; Alisauskiene R; Fathian F; Johnsen E
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):389-396. PubMed ID: 33938520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amisulpride versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Silveira da Mota Neto JI; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD006624. PubMed ID: 20091599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.